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Background: Osteoarthritis (OA) is the most prevalent arthritis worldwide, but the
evolution of pain in relation to joint damage and biochemical markers are not well
understood. We evaluated the relation between clinical pain measures and evoked pain
in relation to structural damage and biochemical biomarkers in knee OA.
Methods: A cross-sectional study in people with knee OA and healthy controls
was conducted. A total of 130 participants with advanced OA requiring total knee
replacement (TKR) (n = 78), mild OA having standard care (n = 42) and non-OA
controls (n = 6), with four drop-outs were assessed. Pain scoring was performed by
the Western Ontario and McMaster Universities OA Index (WOMAC_P) and the Visual
Analog Scale (VAS). Pain sensitization was assessed by pain pressure thresholds (PPTs).
Knee magnetic resonance imaging (MRI) assessed joint damage using the MRI Knee OA
Score (MOAKS). Overall MOAKS scores were created for bone marrow lesions (BMLs),
cartilage degradation (CD), and effusion/Hoffa synovitis (tSyn). Type II collagen cleavage
products (CTX-II) were determined by ELISA.
Results: The advanced OA group had a mean age of 68.9 ± 7.7 years and the
mild group 63.1 ± 9.6. The advanced OA group had higher levels of pain, with mean
WOMAC_P of 58.8 ± 21.7 compared with the mild OA group of 40.6 ± 26.0. All OA
subjects had pain sensitization by PPT compared with controls (p < 0.05). WOMAC_P
correlated with the total number of regions with cartilage damage (nCD) (R = 0.225,
p = 0.033) and total number of BMLs (nBML) (R = 0.195, p = 0.065) using body mass
index (BMI), age, and Hospital Anxiety and Depression Scale (HADS) as covariates.
Levels of CTX-II correlated with tSyn (R = 0.313, p = 0.03), nBML (R = 0.252, p = 0.019),
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number of osteophytes (R = 0.33, p = 0.002), and nCD (R = 0.218, p = 0.042), using
BMI and age as covariates. A multivariate analysis indicated that BMI and HADS were
the most significant predictors of pain scores (p < 0.05).
Conclusion: People with both mild and advanced OA show features of pain
sensitization. We found that increasing MRI-detected joint damage was associated with
higher levels of CTX-II, suggesting that increasing disease severity can be assessed by
MRI and CTX-II biomarkers to evaluate OA disease progression.
Keywords: biomarkers, pain – etiology and drug therapy, sensitization, magnetic resonance imaging, arthritis
INTRODUCTION
Osteoarthritis (OA) is a disease of the whole joint and is
the most prevalent arthritis worldwide (O’Neill et al., 2018).
Recent work has shown how imaging tools such as magnetic
resonance imaging (MRI) and ultrasound (US) can be used to
observe widespread changes in the joint, including in articular
cartilage, underlying bone, with the development of osteophytes
(Ost), subchondral cysts, bone marrow lesions (BMLs), synovitis
(Syn), and joint effusions (Roemer et al., 2016). The two
most significant correlates of pain in OA are Syn and BMLs
(Sofat et al., 2011).
Recent cohort studies, especially of knee OA, have shown how
painful OA is more likely to be associated with Syn measured
by US or MRI and regions of established cartilage loss with
underlying subchondral bony changes and/or BML, which are
associated with more symptomatic disease (Crema et al., 2013;
Deveza et al., 2017; Roemer et al., 2018). In addition, the
biopsychosocial model of pain may explain why people with
relatively modest levels of structural damage in OA may report
high levels of pain and functional impairment (Arendt-Nielsen,
2017). Although there is evidence to suggest that imaging and
biochemical markers are related to OA structural damage and
progression in several studies (Hunter et al., 2011b; Mobasheri
et al., 2017), information from clinical measures (including pain
sensitization), biochemical, and imaging dimensions have rarely
been combined in single reported analyses, so there remains a
lack of clarity in managing pain and functional impairment in
OA using the biomarkers reported (Dam et al., 2009; Gregori
et al., 2018). In the pursuit of new disease modifying OA drugs
(DMOADS), of which several are under investigation, robust
biomarkers of disease severity and progression are urgently
needed for evaluation with clinical outcomes.
Our group and others have previously shown that degradation
products of type II collagen and MRI of the knee represent
biomarkers that show promise as distinctive measures of damage
in painful OA (Hunter et al., 2011a; Kuttapitiya et al., 2017). In
this paper, we demonstrate how pain sensitization is a feature
of mild and advanced OA. We also report how anxiety and
depression factors may influence pain perception in knee OA.
To our knowledge, this is the first study evaluating data on knee
OA for pain sensitization, anxiety and depression scores, MRI
changes measured by the MRI Knee OA Score (MOAKS), and
the biochemical marker CTX-II in a cross-sectional study design
from a UK dataset.
MATERIALS AND METHODS
All procedures were carried out after Ethical approval was
granted (Health Research Authority approval number
12/LO/1970). In order to compare the potential use of biomarkers
for pain, MRI, and biochemical changes, we designed a case–
control study comparing subjects with different stages of OA
pathology. There were three groups in our study: advanced OA,
mild OA, and healthy controls (who did not have arthritis). For
the “advanced OA” group, participants attending the South West
London Elective Orthopaedic Centre were recruited at the time
of assessment for total knee replacement (TKR). Study criteria
for recruitment were as previously described (Kuttapitiya et al.,
2017). The power calculation was made to detect differences
in pain outcome in the “mild OA” and “advanced OA” groups.
The control group was primarily recruited for absence of pain
comparisons and biomarker levels. For the WOMAC Pain
score outcome, we aimed to detect a mean difference of 15
points between the “advanced OA” and “mild OA” groups with
a standard deviation of 26. With 48 subjects per group (“mild
OA” and “advanced OA,” respectively), 80% power with a 0.05
significance level (two sided) is achieved.
The “mild OA” group had knee arthritis under medical
management and physiotherapy. The study sample size
estimation was to recruit at least 100 subjects, and we were able
to recruit 126 subjects whose results could be evaluated.
Study Consent, Control Participants, and
Inclusion/Exclusion Criteria
For subjects with OA, all participants were aged 35–90 years,
had pain, and fulfilled American College of Rheumatology
(ACR) criteria for knee OA (Kuttapitiya et al., 2017). The
reason for the broad age of recruitment reflected the usual
age of presentation for mild OA (younger, aged 35 years
or over) and advanced OA (older, aged 50 years or over).
Subjects were consented by a research associate independent
of the treating physicians, for knee MRI of the target joint
and for waste joint tissue collection at TKR. All participants
with knee OA underwent baseline knee radiography to confirm
knee OA as part of their routine clinical management and
subjects with a Kellgren–Lawrence grade of greater than or equal
to two were recruited. The “mild OA” group was defined as
participants who had painful knee OA and were being managed
with analgesics, e.g., opioids, non-steroidal anti-inflammatory
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drugs (NSAIDs), and/or physical therapies, but were not
deemed by their physician to require joint replacement surgery.
Participants with “advanced OA” knee were those who had
already received full medical management, but still experienced
pain and deemed suitable by their clinician candidates for
TKRs. Exclusion criteria for the “mild” and “advanced” knee OA
groups were: other rheumatologic diagnoses, e.g., rheumatoid
arthritis, systemic lupus erythematosus, pregnancy, regular use of
bisphosphonates, corticosteroids, hormone replacement surgery
in the last 6 months, history of clinically diagnosed depression,
anxiety, or other recent surgery.
Participants without knee OA were recruited as control
subjects. Inclusion criteria for healthy controls were: age 35–
90 years, male or female, no previous history of knee injury,
fractures, OA, or inflammatory arthritis. Exclusion criteria for the
healthy control group were: current use of analgesics, e.g., opioids
or NSAIDs, other rheumatologic diagnoses, e.g., rheumatoid
arthritis, systemic lupus erythematosus, pregnancy, regular use of
bisphosphonates, corticosteroids, hormone replacement surgery
in the last 6 months, history of clinically diagnosed depression,
anxiety, or other recent surgery. Healthy subjects volunteered of
their own free will and were screened for suitability.
Clinical Scores and Pain Assessments
Clinical scores were collected for participants with mild OA,
advanced OA, and healthy controls. The pain subscales for
the Western Ontario and McMaster Universities OA Index
(WOMAC) were recorded for each participant at enrolment
into the study. Participants were asked to score based on
their symptoms in the last 48 h. The WOMAC is a well-
validated pain scoring system and is one of the most widely
used pain assessment tools in OA clinical studies (Bellamy
et al., 2015). We used the WOMACVA3.1 questionnaire, which
comprises of questions for the pain (5 questions), stiffness (2
questions), and function (17 questions) subscales. Since this
report focuses on structural and biochemical correlations with
pain, only results for the WOMAC Pain subscale (WOMAC_P)
are reported. Data for WOMAC stiffness and function scores
are reported elsewhere (Kuttapitiya et al., 2017). In addition
to WOMAC_P, we collected data for all participants for the
Visual Analog Scale (VAS) for pain on a rating scale of 0–
10, since VAS pain is a pain outcome measure recommended
by IMMPACT in clinical pain studies (Dworkin et al., 2005).
Data were collected for body mass index (BMI), defined as
weight/height2, since obesity is a recognized risk factor for OA
development. It is also recognized that anxiety and depression
can influence and impact on pain reporting (O’Neill et al., 2018),
therefore data using the Hospital Anxiety and Depression Scale
(HADS) (Bjelland et al., 2002) were also collected. The HADS
scale consists of 14 questions assessing depression and anxiety.
The questionnaire is scored out of 21, with a score of 0–7
being normal, a score of 8–10 suggesting borderline features
of anxiety or depression, and a score of between 11 and 21
suggesting features of anxiety/depression requiring assessment
and treatment. Quantitative Sensory Testing (QST) by pain
pressure thresholds (PPT) were determined using a Somedic
Algometer as previously described (Kuttapitiya et al., 2017).
Quantitative Sensory Testing by Pain
Pressure Thresholds
Briefly, PPT was performed pre-operatively before knee
replacement. The somatosensory responses were assessed via
pain pressure algometry. Increasing pressure was applied at a
predetermined rate; known as the “slope” (10 kPA/s), to a test
site using a handheld algometer (Algometer Type II, SBMEDIC
Electronics, Solna, Sweden). In this way the subject’s PPT level of
sensitivity to pain and function of non-myelinated C-fibers could
be determined. Test sites were the target knee and contralateral
knee along with three distal points. The knee was sub-divided
into five areas (patella, lateral femur, medial femur, medial tibia,
and lateral tibia) and the distal points included the target lateral
malleolus and the right and left radius. Three readings were taken
at each test point: the first being a test reading. Average PPT
scores are reported for target and contralateral knee (PPT_TK,
PPT_CK) across the five sites, the average for left and right
radius (PPT_R), and for the individual sites of patella of target
and contralateral knee (PPT_TK_Pa and PPT_CK_Pa) and
malleolus (PPT_M).
Biochemical Markers
Biochemical markers were obtained in a subset of patients
and healthy controls. CTX-II levels were determined using
ELISA to detect C-terminal telopeptides of type II collagen
cleavage products from urine samples with creatinine levels for
normalization as previously described (Kuttapitiya et al., 2017).
Urine samples were acquired prior to MRI scans.
Magnetic Resonance Imaging
Magnetic resonance imaging of the target knee was acquired
from OA patients within 6 weeks prior to TKR to enable
visualization of structural changes, including BML, Syn, and
cartilage damage (CD). Data were obtained using a 3T scanner
with an eight-channel knee coil and included sagittal T1-
weighted (TE 15 ms, TR 600 ms) images for delineating knee
anatomical structures and fat-suppressed intermediate-weighted
(TE 30 ms, TR 5000 ms) images in sagittal, coronal, and axial
image planes for visualization of Syn and BMLs (Figure 1). The
multimodal MRI was obtained within 30 min using protocols
that complied with scanner safety procedures with adherence
to any contra-indications for MRI scanning. Radiographic
changes for structural damage features of CD, BMLs, Hoffa and
effusion Syn, and osteophytes (Ost) were evaluated using the
validated MOAKS (Hunter et al., 2011a). MOAKS evaluation was
performed by two consultant radiologists (VE and CH) who were
blinded to the patient’s clinical outcome and group allocation.
Consensus scores were then reached for all of the individual
scores for each anatomical region assessed. The MOAKS variables
were calculated for MRI of the target knee for TKR in subjects
with advanced OA and in the most affected knee for subjects with
mild OA who were managed by usual care with analgesia and
physical therapies.
Magnetic resonance imaging Knee OA Score includes
evaluation over 15 anatomical regions for BMLs, 14 regions
for CD and Ost, and two regions for Syn (Hunter et al., 2011a).
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FIGURE 1 | Measurement of MOAKS scores in subjects with knee OA. (A) Representative MRI scans acquired at 3T with an eight channel knee coil for patients with
advanced OA. (A) Sagittal T1-weighted image with TE 15 ms, TR 600 ms, Subject 38, average cartilage damage score (CD_load) = 94. (B) Coronal intermediate
weighted image with TE 30 m, TR 5000 ms, fat saturation, 0.35 mm in plane resolution, 3 mm slice thickness, 0.25 mm slice gap, SENSE factor 1.4. Subject 58,
total synovitis score (total_Syn) = 3 (range 0–6), whole knee scores for BML (BML_load) = 44 (range 0–125), CD (CD_load) = 46 (range 1–94), and osteophytes
(Ost_load) = 19 (range 0–38). Ranges given are the minima and maxima over the whole patient data set. (C) Comparison of MOAKS’ defined structural damage in
knee OA in advanced versus mild OA. Significant differences by Mann–Whitney U-test were: †p < 0.05, †††p < 0.001 between advanced and early OA groups. Syn,
synovitis; BML, bone marrow lesion; CD, cartilage degradation; Ost, osteophyte.
The individual MOAKS values were combined to provide
global measures of damage to enable creation of continuous
variables that could be used in correlation analysis with clinical
and biomarker parameters. Hoffa and effusion Syn score were
combined to create a total Syn score (Total_Syn). The number
of BMLs were summed over all anatomical regions to give
the total number over the whole knee (nBML). A similar
process was performed for the number of regions identified
with CD (nCD) and for the number of osteophytes (nOst).
For BMLs a lesion load score was evaluated as the product
of number of lesions, lesion size score, and the % area score
of lesion size, for each of the individual regions evaluated
in MOAKS. These individual scores were then summed to
give a whole knee lesion load (BML_load). A similar process
was performed for CD and Ost by summing the product of
number of lesions with lesion size scores over these same
anatomical regions to give load scores (CD_load, Ost_load)
for the whole knee.
Statistical Analysis
Data were analyzed using IBM SPSS Statistics 25 and statistical
significance was considered at a threshold of p < 0.05. We
make no explicit multiplicity corrections for this exploratory
data analysis. The Mann–Whitney U-test was used for group
comparisons and bivariate analysis using a direct Pearson
correlation and with suitable covariates and was used to assess
relationships between pairs of all clinical, MRI, and fluid
biomarker parameters.
A multivariate analysis was performed using the Automatic
Linear Modeling module in SPSS, which is a regression technique
that determines a linear combination of a defined set of
parameters that best describes the variability of a specific
dependent variable. The dependent variables assessed were the
VAS and WOMAC pain scores, the PPT at the patella, and the
urinary biomarker CTX-II. We assessed how these parameters
related to the structural damage observed by MRI as defined
by the MOAKS load scores for BML, CD, Ost, and the total
Syn. BMI and Age were also included in the model and for
the pain scores HADS was additionally included. Data sets were
preselected to include only those for which all parameters were
available for each analysis. The adjusted r-squared was used for
the optimization parameter and all parameters were used in the
“best-fit” option. We report the significant coefficients of the
linear modal and the overall accuracy of the fit.
For MRI measurements recorded for the two scorers (VE and
CH), inter-rater reliability and correlation were calculated using
Kendall’s tau-b, which is suitable for ordinal data and Spearman
correlation. We assessed the reliability across the BML, CD, and
Ost MOAKS scores at the level of individual anatomical regions,
as well for the total number of lesional regions per patient for
BML, Ost, and CD. In accordance with reliability criteria set by
Landis and Koch (1977), 0.61–0.8 suggests very good reliability,
while 0.81–1.0 suggests near perfect agreement.
Data from all investigations were not available for all
participants, hence statistical calculations were performed across
the maximum possible number of patients within each analysis.
RESULTS
Our cross-sectional study identified a total of 120 participants
at distinct stages of management by standard care for their
OA. Subjects were evaluated in two OA groups: the “advanced
OA” group (n = 78) who underwent TKR for knee OA, and
a “mild OA” group who were being treated with medical
management (n = 42). All subjects were prescribed NSAIDs or
opioid analgesics for their arthritic pain. Clinical information
and pain scores were obtained from all 120 participants, QST
measurements from n = 118, wet biomarkers quantified from
n = 112, and MRI performed on n = 93 OA patients. In a
third “healthy control” group (n = 6) who had no evidence of
arthritis we obtained pain scores, wet biomarker levels, and PPT
measurements for indicative comparisons with the participants
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TABLE 1 | Study demographics.
Advanced OA group Mild OA group Healthy volunteers
Parameter (n = 78) (n = 42) (n = 6)
Age (year) Age range (year) 68.9(7.7)††51− 88 64.1(9.6)47− 85 45.0(5.6)∗∗∗36− 51
Female, N (%) 50(64) 30(71) 6(100)
Body mass index (kg m−2) 32.3(5.6)†† 29.2(4.7) 23.3(3.6)∗∗∗
WOMAC pain (0–100) 58.8(21.7)††† 40.6(26.0) 0.6(1.4)∗∗∗
VAS pain (0–10) 5.8(2.3)††† 3.7(2.8) 0(0)∗∗∗
HADS (0–20) 12.5(7.1) 13.3(7.4) 7.5(5.8)
PPT (kPa) 394(223) 423(227) 690(192)∗∗
Clinical management Total knee replacement Medical management None
Study demographics are shown as mean and standard deviation in parentheses. WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index; VAS, Visual
Analog Scale; HADS, Hospital Anxiety and Depression Scale; PPT, pain pressure threshold. Significant differences with a Mann–Whitney U-test were: ∗∗p < 0.01,
∗∗∗p < 0.001 between healthy controls and all OA subjects. ††p < 0.01, †††p < 0.001 between advanced and mild OA groups. A Chi-squared test was performed to
evaluate any female proportion comparisons. This showed a Chi-square value of 3.60, degrees of freedom 2, with a p-value of 0.16.
with OA. There were four drop-outs in the study where data
could not be assessed.
Study demographics (Table 1) showed significantly higher
BMI, WOMAC Pain (WOMAC_P), and VAS, with significantly
lower patella PPT (Table 2) in participants with OA (advanced
and mild groups) compared with healthy non-OA controls.
WOMAC_P and VAS were higher in participants with advanced
OA compared with mild OA. A Chi-squared comparison did not
show any significant differences in gender in each of the groups
(p = 0.16). The comparison to healthy volunteers is considered
of importance due to the significant clinical differences (Table 1)
between these groups. The healthy controls had no evidence of
pain or OA clinically. Although the healthy control group was
significantly younger than the OA groups, they were recruited for
age and lack of OA or pain at the age when OA often first presents
(aged 45 years or over). Since the age range for recruitment into
the study included subjects from 35 to 90 years, due to the wide
age range for OA presentation, the differences in age for our three
groups are reflected by this. Subjects with advanced OA were the
oldest (mean age 69 years) and had the highest levels of pain
and MRI-reported structural damage, with the mild OA group
being slightly younger with a mean age of 64 years. Although
the healthy control group were significantly younger than the
OA groups, with a mean age of 45 years, they were recruited for
meeting criteria for age and lack of OA or pain at the age when
OA often first presents (aged 35 years or over).
Evoked pain assessed by QST showed that PPT levels
were significantly lower in OA subjects compared to controls
for PPT_TK_Pa (p = 0.028), PPT_CK_Pa (p = 0.036), and
PPT_TK_M (p = 0.036) (Table 2). There were no significant
differences (p ranging from 0.320 to 0.910) between PPT
measurements at the patella of target knee (PPT_TK_Pa) and
contralateral knee (PPT_CK_Pa), or of averages over the whole
target/contralateral knees (PPT_TK, PPT_CK), radius/malleolus
(PPT_TK_M, QST_TK_R), suggesting evidence of central
sensitization in both mild and advanced OA groups.
The MOAKS was used to assess structural damage in
the mild and advanced OA groups (Figure 1). The inter-
rater reliability of MRI-assessed MOAKS showed moderate
but significant agreement, with an average Kendall’s tau-b of
0.51 (range 0.39–0.66) and average Spearman correlation of
0.59 (range 0.48–0.71), demonstrating good agreement between
the two readers (see Supplementary Table 1). For measures
of MOAKS evaluated structural knee damage, there were
significant differences between the advanced and mild OA
groups, with statistically significant higher structural damage in
the advanced OA group compared with the mild OA group.
This included numbers of regions of BMLs (nBML), cartilage
degradation (nCD), nOst, in addition to the overall load scores
for BML_Load, CD_Load, and Ost_Load (Figure 1C). The
severity of effusion Syn was significantly higher in advanced
compared with mild OA (p < 0.05), but no significant difference
in Hoffa’s or total Syn.
We measured urinary type II collagen degradation products
(CTX-II) by ELISA in all three study groups (Figure 2). For
CTX-II values, the minimum value was 120 ng/mmol, with the
maximum 1808 ng/mmol. The range was 1688 ng/mmol. The
mean CTX-II value was 450.2 ng/mmol with a SD of 302.2.
The coefficient of variation across replicate measurements was
67%. Levels of CTX-II were significantly higher in advanced OA
TABLE 2 | Quantitative sensory testing (QST) by pain pressure thresholds
(PPTs) in knee OA.
Advanced OA group Early OA group Healthy volunteers
Parameter (N = 76) (N = 42) (N = 6
PPT_TK_Pa 392(225) 423(227) 690(192)∗∗
PPT_CK_Pa 427(327) 453(210) 628(62)∗
PPT_TK 366(214) 339(155) 454(115)
PPT_CK 376(179) 367(153) 452(99)
PPT_TK_M 345(183) 359(164) 1020(231)∗∗∗
PPT_R 381(186) 374(143) 500(63)
PPTs are shown as mean and standard deviation in parentheses in kPa. Significant
differences with a Mann–Whitney U-test were: ∗p< 0.05, ∗∗p< 0.01, ∗∗∗p< 0.001
between healthy controls and all OA subjects. There were no significant differences
between advanced and early OA groups (p > 0.3). PPT, pain pressure threshold;
PPT_TK_Pa, PPT for the target knee at the patella; PPT_CK_Pa, PPT at the
contralateral patella; PPT_TK, PPT at for the whole knee; PPT_CK, PPT for the
contralateral knee; PPT_TK_M, PPT for the target knee side at the malleolus;
PPT_R, PPT at the right radius.
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FIGURE 2 | Type II collagen degradation product expression in study. (A) Comparison between urinary CTX-II levels in study groups in ng/mmol. ∗∗p < 0.01,
between healthy controls and all OA patients; †††p < 0.001 between advanced and early OA groups. (B) Variation in levels of CTX-II by subject group and age.
Group 0, healthy controls; Group 1, mild OA; Group 2, advanced OA.
in comparison to mild OA (p < 0.001). Urinary CTX-II levels
were significantly higher in mild and advanced OA compared
with healthy controls (p < 0.01). We found that urinary CTX-
II levels increased with worsening severity of OA and increased
with age (Figure 2).
Bivariate correlation analysis showed significant correlations
between most of the measured parameters (Supplementary
Tables 1, 2). In particular there were strong correlations between
the different pain scores (VAS, WOMAC_P, PPT) and between
the pain scores and BMI, age, and HADS, as well as between VAS
and WOMAC_P and MRI scores of damage (Supplementary
Table 2). Therefore, BMI, age, and HADS were used as covariates
and included in the multivariate analysis to assess how pain
related to structural damage. Since CTX-II was significantly
correlated with BMI and almost significantly correlated with
age (Supplementary Table 2), BMI and age were used as
covariates and included in the multivariate analysis to assess
how CTX-II related to structural damage. The direct correlation
of CTX-II to structural damage determined by MOAKS scores
for numbers of Ost, BMLs, CD, and total Syn is shown in
Figure 3 for mild and advanced OA (Figure 3), with the
strongest correlations shown for total Syn. When evaluating the
whole dataset of mild and advanced OA combined with BMI
and age as covariates, we still found a significant correlation
between CTX-II levels and total Syn (total_Syn) (R = 0.313,
p = 0.03), number of Ost (R = 0.330, p = 0.002), number
of BML (R = 0.252, p = 0.019), and number of regions of
CD (R = 0.218, p = 0.042). We also found CTX-II levels
correlated with lesion load scores for CD (R = 0.277, p = 0.009)
and BML (R = 0.308, p = 0.004). A multivariate analysis
using automatic linear modeling determined that the most
significant parameters that determined the CTX-II levels were
Ost load and total Syn (p < 0.05) with a predictive accuracy of
23% (Figure 4).
Multivariate analysis for the pain scores as dependent variables
showed that HADS was a highly significant factor (p = 0.006) in
determining pain for VAS, WOMAC, and PPT, and BMI a very
significant factor (P < 0.001) for VAS and WOMAC (Figure 4).
Only for VAS were there significant predictive effects related to
age and to MRI via the Ost load. However, the predictive accuracy
was only moderate for VAS and WOMAC at 33% and 32%,
respectively, and very low at 9% for PPT.
DISCUSSION
Knee OA is a multifactorial condition which produces pain and
exhibits damage to cartilage, bone, and the development of Syn.
Biomarkers are urgently needed to aid patient stratification and
for developing improved treatment strategies. We investigated
how CTX-II generated during OA, relates to MRI features of
knee damage, and showed the most significant relationships
were to Syn and Ost. In our study we have shown that pain
sensitization was found in mild and advanced OA subjects.
We also found PPT measures were not strongly related
to structural damage (Figure 4). The strongest associations
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FIGURE 3 | Relation of CTX-II to MRI-defined structural damage in knee OA. Pearson correlation of CTX-II levels with (A) the number of osteophytes (nOsteophyte)
(p = 0.003), (B) the number of bone marrow lesions (nBMLs) (p = 0.005), (C) the number of regions of cartilage degradation (nCD) (p = 0.002) and with (D) the total
synovitis total_Syn (p = 0.001). Group 1, mild OA group; Group 2, advanced OA group; Syn, synovitis; BML, bone marrow lesion; CD, cartilage degradation; Ost,
osteophyte.
of WOMAC and VAS reported pain were to HADS and
BMI, indicating the difficulty of assigning pain directly to
measures of structural damage when there are psychological
and physiological confounds in the individual’s perception
of pain, and difficulty in deriving causal relationships. We
have shown, to our knowledge for the first time, that by
combining biomarkers derived from damaged tissue, including
type II collagen degradation products and MRI-detected Syn,
BMLs, and CD, they can be used to track progression in
painful knee OA. The biomarkers we propose could also be
used to assess response to future therapeutic interventions
including DMOADS.
We found that patient reported pain by WOMAC_P was
significantly elevated in people with advanced and mild OA.
Pain in OA is thought to arise from richly innervated structures
including the synovium and bone, with more recent work
reporting expression of neurotrophic factors such as nerve
growth factor (NGF) at the osteochondral junction (Sofat
et al., 2011). A number of studies have suggested that pain
sensitization in OA is mediated by neurotrophic factors expressed
within several joint compartments, including the synovium
and osteochondral junction (reviewed in Sofat et al., 2011;
Neogi et al., 2015; Kuttapitiya et al., 2017). With respect to
structural damage assessed by MOAKS, in direct correlations
we found that the number of affected regions, rather than the
estimated lesion load, most strongly correlate with WOMAC
pain (Supplementary Table 2), suggesting it is the development
of multiple damage sites that relate to increased pain levels
rather than the severity of damage at these sites. However,
a multivariate analysis indicated that BMI and HADS were
the most significant predictors of pain scores (Figure 4),
indicating the complexity of assigning pain directly to measures
of structural damage. Overall knee PPT measures were not
significantly different between advanced and early OA, and
not directly related to structural damage. Neogi et al. (2015)
have previously shown that pain sensitization is a significant
feature in OA and is related to Syn but not BMLs. Our
data contribute further to observations of pain sensitization
in OA by demonstrating that sensitization is also detected in
early OA disease and could reflect a feature of a threshold
of joint damage which is required for sensitization features
to develop. We also found that pain sensitization measured
by PPT was significantly related to anxiety and depression
scores, suggesting a strong psychological component to pain
in knee OA, as suggested by other studies (Arendt-Nielsen,
2017; Deveza et al., 2017; O’Neill et al., 2018). Our data
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FIGURE 4 | Regression analyses of clinical, biochemical, and structural parameters in knee OA. (A,B) Multivariable regression analyses were conducted for
continuous variables including VAS, WOMAC pain, urinary CTX-II, MOAKS-defined damage including bone marrow lesion load (BML_Load), total synovitis
(total_Syn), cartilage degradation load (CD_Load), osteophyte load (Ost_Load), pain pressure thresholds (PPT), and Hospital Anxiety and Depression Scale (HADS).
Regression analysis is shown for the urinary type II collagen degradation product biomarker (CTX-II) in relation to structural damage by osteophytes and synovitis.
Covariates were BMI and age in the analysis. Analyses are presented with p-values, coefficients, and standard error. There were 78 degrees of freedom.
show that subjects with advanced OA were older than people
with early OA and healthy controls. The advanced OA group
had more severe disease as evidenced by greater structural
damage by MRI and higher pain scores. With advancing
age, OA severity tends to increase, as does BMI, which
we also observed.
We found that urinary CTX-II degradation products
are strongly related to structural damage and particularly
to measures of Ost and Syn. The synovium is a richly
innervated part of the joint and has been proposed as a
major mediator of pain in OA (Hunter et al., 2011a; Neogi
et al., 2015). CTX-II is complementary to pain scores and
has potential as a surrogate marker (e.g., in the absence
of MRI) of overall damage to aid patient stratification for
therapy. Since Syn and Ost are known features of tissue
damage in OA, our findings suggest that structures including
synovium and bone may be a source of enzymes such as
matrix metalloproteinases which are implicated in type II
collagen degradation by our group (Kuttapitiya et al., 2017)
and others (Nielsen et al., 2008) and not just cartilage as was
traditionally described.
The importance of type II collagen degradation has been
demonstrated in animal models. In a rat model of OA using
anterior cruciate ligament (ACLT) resected rats, Nielsen et al.
(2008) showed that protein extracts and histology demonstrated
C-terminal telopeptide of type II collagen in protein extracts
and histology that was greater than sham-operated rats. CTX-II
epitopes were also detected in ACLT resected rat joint sections
(Nielsen et al., 2008). In human studies, samples analyzed from
the OA initiative (OAI) showed that higher levels of urinary
CTX-II were correlated with patellar damage by MRI (R = 0.19,
p = 0.04) (Joseph et al., 2018). A recent analysis evaluated
if urinary C-terminal telopeptide of type II collagen (CTX-
II) levels are different between people with OA and healthy
non-OA controls (Huang et al., 2017). In a meta-analysis,
Huang et al. (2017) found CTX-II levels were higher in subjects
with OA than in controls. A subgroup analysis showed that
CTX-II levels rose with increasing OA severity, suggesting
that type II degradation products of type II collagen may be
a promising biomarker for OA. Companies have developed
ELISAs for Type II collagen degradation specific neoepitopes;
Bay-Jensen et al. (2011) developed ELISAs measuring CIIM in
synovial fluid/serum, with both compartments showing higher
CIIM in OA compared with non-OA samples (p < 0.05).
Other groups have also reported the validity of using CTX-
II degradation products as a biomarker for OA (Van Spil
et al., 2015). Data from the CHECK cohort showed that
urinary CTX-II levels showed positive associations with Ost
area and negative associations with minimum joint space width
(Van Spil et al., 2015).
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Our study demonstrates that the burden of increasing
structural damage in different compartments of the joint, i.e.,
cartilage, bone, and synovium, are all strongly linked to each
other as well as to measures of clinical pain reporting (VAS
and WOMAC_P) but not to the evoked pain evaluated by pain
sensitization measures (Figure 4 and Supplementary Table 2),
suggesting PPT is an important independent parameter for
characterizing OA subjects. Many reports have investigated
structural damage parameters, including BMLs and Syn,
independently of each other (Kornaat et al., 2007; Dam et al.,
2009; Collins et al., 2016; Everhart et al., 2019). Analysis from
the OAI has demonstrated that cartilage defects are independent
risk factors for joint replacement in knee OA over a 9-year
observation period (Everhart et al., 2019), supporting findings
from our study that greater cartilage defects are associated
with more symptomatic pain requiring treatment (Figure 1).
We also found that greater levels of MOAKS’ derived Syn is
associated with higher levels of reported pain, as suggested by
other studies (Collins et al., 2016). In a nested case–control study
conducted as part of the Foundation for the National Institutes
of Health Biomarkers Consortium Project (FNIH), cartilage
thickness, cartilage morphology, effusion Syn/Hoffa Syn, and
meniscal pathology were associated with OA progression over
2 years using a multivariable logistic regression model (Collins
et al., 2016), suggesting that biomarkers which incorporate
structural changes including CD and Syn in relation to symptom
progression, as we found in our study, could be very useful
markers in future studies of novel therapeutic agents. Other
studies have supported our finding that type II collagen
degradation and MRI-detected tissue damage can be used to
compare the diagnostic and predictive abilities of different
combinations of imaging and biochemical markers to track OA
progression and severity (Collins et al., 2016). However, our study
found greater correlation between distinct structural damage
parameters including BMLs, CD, Ost load, and Syn than previous
cohort studies. The reason for the differences found may be that
we used a cross-sectional study design in comparison to other
studies of longitudinal cohorts (Van Spil et al., 2015; Joseph et al.,
2018), thereby finding greater correlation with a broader range of
damage features than the distinct changes in structures found in
longitudinal studies. More recently, a machine learning algorithm
has been used to combine data from the FNIH Biomarkers
Consortium to show that MRI-based structural damage measures
were better predictors of OA progression than biochemical
markers (Nielsen et al., 2008). In contrast, baseline variables that
contributed to progression included BMLs, Ost, medial meniscal
extrusion, and urine C-terminal cross-linked type II collagen
telopeptide (Nelson et al., 2019).
Limitations of our study include the fact that data at one time
point only were evaluated in our cross-sectional analysis. The
potential of confounding factors for age and BMI in introducing
bias in our study results were also a consideration; therefore,
data were corrected for covariates including age and BMI where
possible. Bias can occur when recruiting subjects into clinical
studies, especially since we had a wide age range for recruitment
into the study. We aimed to reduce bias as much as possible by
recruiting consecutive subjects who were referred to our clinical
services consecutively, provided they gave consent. For healthy
controls, they were recruited in an unbiased manner as much
as possible through adverts placed in clinic areas. To follow-
on from our cross-sectional study, future longitudinal studies of
our cohort will be needed to evaluate long-term outcomes for
pain, function, and biomarkers. Our analysis will also be aided
by future interrogation of wet biomarkers in particular in larger
longitudinal cohort studies. Although we determined significant
correlations between pain measures and the fluid marker CTX-
II, with measures of structural damage (Figure 4), the accuracy
was low suggesting there may be other factors determining pain
that we have not taken into account (e.g., MRI structural damage
scores were of the most painful knee, but pain and CTX-II
measures are whole body related). A limited number of healthy
controls were studied to obtain indicative parameterization of
CTX-II and PPT scores in disease-free volunteers at an age close
to early OA. Further studies with a larger control cohort across
the full age range are still needed to fully determine threshold
levels related to disease, as in this study our primary aim was to
evaluate relationships between structural, fluid biomarkers, and
pain parameters within the OA groups.
CONCLUSION
In summary, data from our study demonstrate how people
with both mild and advanced OA have features of pain
sensitization, which is likely triggered by tissue damage in OA in
several compartments, including bone, cartilage, and synovium.
The MRI and urinary CTX-II biochemical biomarkers that
we identified have potential use in the clinic to assess and
monitor response to treatments in painful knee OA, a prevalent
condition in which robust biomarkers are needed to assess disease
progression and guide treatments.
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